| Literature DB >> 29749406 |
Antonella Virgilio1, Teresa Amato1, Luigi Petraccone2, Francesca Esposito3, Nicole Grandi3, Enzo Tramontano3, Raquel Romero4, Shozeb Haider4, Isabel Gomez-Monterrey1, Ettore Novellino1, Luciano Mayol1, Veronica Esposito5, Aldo Galeone6.
Abstract
In this paper, we report our investigations on analogues of the anti-human immunodeficiency virus type 1 (HIV-1) integrase (IN) aptamer T30175 in which the individual thymidines forming the loops were replaced by 5-hydroxymethyl-2'-deoxyuridine residues (H). Circular dichroism, nuclear magnetic resonance and gel electrophoresis investigations clearly indicated that all the modified aptamers preserve the ability to form the original 5'-5' end-stacked head-to-head dimeric G-quadruplex structure, in which each G-quadruplex adopts a parallel arrangement and is characterized by three G-tetrads, three propeller loops and one bulge-loop. All the modified aptamers were tested in an IN inhibition LEDGF-independent assay. While the modified aptamers INTB-H13 and INTB-H17 showed IC50 values comparable with that of the parent aptamer (INTB-nat), analogues INTB-H2, INTB-H5 and, to a lesser extent, INTB-H9 showed a higher ability to inhibit the HIV IN than the unmodified aptamer. Molecular modelling studies evaluating the aptamer/HIV IN interaction highlighted the ability of the modified thymidines to establish several contacts with the target protein. All the data point to the importance of loops in the aptamer/target interaction and suggest that the site-specific replacement of loop residues with commercially available analogues can be considered a straightforward strategy to improve the biological activities of several G-quadruplex aptamers.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29749406 PMCID: PMC5945619 DOI: 10.1038/s41598-018-25720-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Schematic representation of the dimeric G-quadruplex structure adopted by aptamer T30175 and chemical structure of thymidine (T) and 5-hydroxymethyl-2′-deoxyuridine (H), introduced in positions 2, 5, 9, 13 and 17. All the guanosines adopt anti glycosidic conformations (in light blue). The thymidines are represented as black circles.
Name, sequence, melting temperature and binding energy to HIV-1 IN of the ODNs investigated.
| Name | Sequence* | Tm (°C) (±1) | Binding energy (Kcal/mol) |
|---|---|---|---|
| 5′-GTGGTGGGTGGGTGGGT-3′ | 61 | −110.0 | |
| 5′-GHGGTGGGTGGGTGGGT-3′ | 63 | −139.1 | |
| 5′-GTGGHGGGTGGGTGGGT-3′ | 62 | −137.2 | |
| 5′-GTGGTGGGHGGGTGGGT-3′ | 61 | −133.4 | |
| 5′-GTGGTGGGTGGGHGGGT-3′ | 63 | −132.2 | |
| 5′-GTGGTGGGTGGGTGGGH-3′ | 59 | −132.9 | |
| 5′-TTGTGGTGGGTGGGTGGGT-3′ | 74 | N.T. |
*H = 5-hydroxymethyl-2′-deoxyuridine; see main text for details. N.T. = not tested.
Figure 2Imino proton regions of the 1H-NMR spectra (500 MHz) of the ODNs investigated. See main text for details.
Figure 3CD spectra of the ODNs investigated. Conditions: 20 °C in potassium phosphate buffer (1 mM KH2PO4/K2HPO4, 3 mM KCl, pH 7.0) at 35 µM ODN strand concentration. INTB-nat (black dashed line), TT-INTB-nat (grey dashed line), INTB-H2 (black dashed dotted line), INTB-H5 (black solid line), INTB-H9 (black dotted line), INTB-H13 (grey dotted line) and INT-BH17 (grey solid line).
Figure 4PAGE analysis of the natural and modified ODN sequences investigated. Lane 1: INTB-nat; lane 2: INTB-H2; lane 3: INTB-H5; lane 4: INTB-H9; lane 5: INTB-H13; lane 6: INTB-H17; lane 7: TT-INTB-nat.
ODN inhibition of the HIV-1 IN LEDGF/p75-independent activity.
| Compound | aIC50 IN LEDGF-independent integration (µM) |
|---|---|
| 0.145 ± 0.005 | |
| 0.150 ± 0.030 | |
| 0.178 ± 0.002 | |
| 0.225 ± 0.005 | |
| 0.225 ± 0.045 | |
| 0.270 ± 0.020 | |
|
| 0.058 ± 0.010 |
aCompound concentration required to inhibit the HIV-1 IN catalytic activities, in the absence of LEDGF, by 50%. Raltegravir has been used as a reference. See main text for details.
Figure 5(A) Details of the interactions formed by the H residue at position 2 in chain A and (B) chain B of the aptamer INTB-H2. (C) Side view and (D) top view of the protein-aptamer complex. HIV1-IN has been coloured beige and represented as a surface, the aptamer INTB-H2 has been represented as a cartoon and coloured in light cyan.